Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. (Q51491050)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Olga Favorova

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Ekaterina Y Tsareva

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Olga G Kulakova

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Alexey N Boyko

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sergey G Shchur

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Dmitrijs Lvovs

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Alexander V Favorov

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Evgeny I Gusev

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

23 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

43-53

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Pathogenesis of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Disease-modifying drugs for multiple sclerosis: current and future aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

The mechanism of action of glatiramer acetate treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Role of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: role of IGF-2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

TGFβ directs gene expression of activated microglia to an anti‐inflammatory phenotype strongly focusing on chemokine genes and cell migratory genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Pharmacogenomics and multiple sclerosis: moving toward individualized medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Linkage and association of proinflammatory cytokines genes IL-6, IFNG and TNF with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

Complex analysis of association of inflammation gene polymorphisms with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.11.136

21 January 2018

Identifiers

DOI

10.2217/PGS.11.136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22111603%20AND%20SRC:MED&resulttype=core&format=json

release_qgvviuayoran7kak6kagk7vyoi

17 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qgvviuayoran7kak6kagk7vyoi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference